FDA Approval of Vanda’s Bipolar I Therapy Sparks Sharp Stock Rally
FDA granted approval to Vanda Pharmaceuticals' Bipolar I disorder drug on Feb. 21, 2026, triggering a sharp rally in the company's shares. The clearance opens the US market for a new therapy addressing acute manic episodes in bipolar I patients.
1. FDA Approval of Bipolar I Therapy
On Feb. 21, 2026, the FDA approved Vanda Pharmaceuticals’ new treatment for bipolar I disorder, marking a regulatory milestone for the company. The decision clears the way for Vanda to introduce its therapy in the US mental health market.
2. Shares Jump on Approval News
Following the approval announcement, Vanda’s shares surged sharply as investors anticipated robust sales and significant market uptake. The rally underscores market optimism around the therapy’s potential to address unmet needs in acute manic episodes.
Related News
NVDA
Nvidia Posts 85% Revenue Surge to $81.6B, Forecasts $91B Next Quarter
NVDA•
MMYT
MakeMyTrip Q4 Cash Hits $782M with 1.82% Margin and 15.2% Accommodation Growth
MMYT•
NVDA
Nvidia Cuts China From Outlook, Highlights $1 Trillion Hyperscaler Capex Forecast
NVDA•
ING
ING-backed euro stablecoin consortium grows to 37 banks, eyes H2 launch
ING•
NTES
NetEase Q1 Revenue Hits RMB30.6 Billion; Gross Profit Jumps 14.8%
NTES•
Sources
F